Merck says Phase 2 CADENCE shows WINREVAIR cuts PVR in CpcPH-HFpEF

Reuters03-29 23:45
Merck says Phase 2 CADENCE shows WINREVAIR cuts PVR in CpcPH-HFpEF
  • Merck disclosed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) met primary endpoint in adults with CpcPH-HFpEF, cutting pulmonary vascular resistance by 1.02 Wood units at week 24 on 0.3 mg/kg versus placebo (p=0.004).
  • Higher 0.7 mg/kg dose reduced pulmonary vascular resistance by 0.75 Wood units versus placebo at week 24 (p=0.024).
  • Data were presented at ACC.26 in a late-breaking session, with simultaneous publication in Circulation.
  • Merck plans to move WINREVAIR into registrational Phase 3 development for CpcPH-HFpEF, citing 0.3 mg/kg as potential best benefit-risk dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603291145BIZWIRE_USPR_____20260329_BW952162) on March 29, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment